| 56. | Weise D, Paus S. Dystonien: Diagnostische und therapeutische Herausforderungen. Neurologie up2date 2022;5:341–358. |
| 55. | Güresir E, Gräff I, Seidel M, Bauer H, Coch C, Diepenseifen C, Dohmen C, Engels S, Hadjiathanasiou A, Heister U, Heyer I, Lampmann T, Paus S, Petzold G, Pöhlau D, Putensen C, Schneider M, Schuss P, Textor J, Velten M, Wach J, Welchowski T, Vatter H. Aneurysmal Subarachnoid Hemorrhage during the Shutdown for COVID-19. J Clin Med 2022;11(9):2555. |
| 54. | Jost WH, Bäumer T, Bevot A, Birkmann U, Buhmann C, Grosheva M, Guntinas-Lichius O, Mlynczak U, Paus S, Pflug C, Schröder S, Steffen A, Wilken B, Berweck S. Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults. Fortschr Neurol Psychiatr 2022;90(5):212-221. |
| 53. | Park J, Reilaender A, Petry-Schmelzer J, Stöbe P, Cordts I, Harmuth F, Rautenberg M, Woerz S, Demidov G, Sturm M, Ossowski S, Schwaibold E, Wunderlich G, Paus S, Saft C, Haack T. Transcript-specific loss-of-function variants in VPS16 are enriched in dystonia patients. Neurol Genet 2022;8(1):e644. |
| 52. | Grobe-Einsler M. Urbach H, Paus S. Recurrent pontine strokes in a young male. J Stroke and Cerebrovasc Dis 2020;29:105386. |
| 51. | Traschütz A, Hattingen E, Klockgether T, Paus S. Mirror movements and blepharoclonus as novel phenomena in hereditary diffuse leukoencephalopathy with spheroids. Parkinsonism Relat Disord 2019;58:83-84. |
| 50. | Martin JA, Zimmermann N, Scheef L, Jankowski J, Paus S, Schild HH, Klockgether T, Boecker H. Disentangling motor planning and motor execution in unmedicated de novo Parkinson's disease patients: An fMRI study. Neuroimage Clin 2019;22:101784. |
| 49. | Marek M, Grobe-Einsler M, Bedarf JR, Wabbels B, Paus S. Sexual dysfunction in cervical dystonia and blepharospasm. Neuropsychiatr Dis Treat 2018;14:2847-2852. |
| 48. | Bedarf JR, Nelles M, Reimann J, Paus S, Zimmermann J. Teaching Video NeuroImages: Propriospinal myoclonus as a sequela of Guillain-Barré syndrome. Neurology 2018;91(3):e297e299. |
| 47. | N. Brüggemann N, Lohmann K, Paus S, Lohmann E, Gasser T, Ganos C, Klein C. Monogenic dystonias. Nervenheilkunde 2018;37(03):159-166. |
| 46. | Marek M, Linnepe S, Klein C, Hummel T, Paus S. High prevalence of olfactory dysfunction in cervical dystonia. Parkinsonism Relat Disord 2018;53:33-36. |
| 45. | Reichel G, Kamm C, Kang J-S, Müngersdorf M, Paus S, Reuter I, Stenner A, Weise D. Die zervikalen Dystonien. Fortschr Neurol Psychiatr 2018;86(6):368-386. |
| 44. | Dafotakis M, Paus S. Bedeutung der Neurophysiologie bei psychogenen neurologischen Störungen. Klin Neurophysiol 2017;48:187-199. |
| 43. | Rácz A, Paus S, Elger CE, Surges R. Video-EEG findings in acute bithalamic-midbrain ischemia. J Neurol Sci 2017;380:16-18. |
| 42. | Bedarf JR, Kebir S, Michelis JP, Wabbels B, Paus S. Depression in blepharospasm: A question of facial feedback? Neuropsychiatr Dis Treat 2017;13:1861-1865. |
| 41. | Michelis JP, Hattingen E, Gaertner FC, Minnerop M, Träber F, Biskup S, Klockgether T, Paus S. Expanded phenotype and hippocampal involvement in a novel compound heterozygosity of adult PLA2G6 associated neurodegeneration (PARK14). Parkinsonism Relat Disord 2017;37:111-113. |
| 40. | Hentschel F, Dressler D, Abele M, Paus S. Impaired heart rate variability in cervical dystonia is associated to depression. J Neural Transm (Vienna) 2017;124(2):245-251. |
| 39. | Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Schoenle PW, Shahidi GA, Walter U, Saberi FA. BoNT therapy for treatment of spasticity in MS: review and recommendations of the IAB-Working Group for Movement Disorders task force. J Neurol 2017;264(1):112-120. |
| 38. | Petschow C, Scheef L, Paus S, Zimmermann N, Schild HH, Klockgether T, Boecker H. Central Pain Processing in Early-Stage Parkinson's Disease: A Laser Pain fMRI Study. PLoS One 2016;11(10):e0164607. |
| 37. | Michelis JP, Zimmermann J, Bedarf JR, Bundschuh R, Gaertner FC, Paus S. Facial movement disorder and dopamine imaging in a patient with amphetamine abuse. Parkinsonism Relat Disord 2016;31:153-155. |
| 36. | Urbach H, Rauer S, Mader I, Paus S, Wagner J, Malter MP, Prüss H, Lewerenz J, Kassubek J, Hegen H, Auer M, Deisenhammer F, Ufer F, Bien CG, Baumgartner A. Supratentorial white matter blurring associated with voltage-gated potassium channel-complex limbic encephalitis. Neuroradiology 2015;57(12):1203-1209. |
| 35. | Bedarf JR, Marek M, Bien CG, Elger CE, Paus S. Sustained effect of botulinum neurotoxin in myoclonus due to Epilepsia partialis continua. Mov Disord Clin Pract 2015;2(4):402-406. |
| 34. | Sajonz BE, Mädler B, Herberhold S, Paus S, Allert N, Coenen VA. Stimulation induced hypogeusia in thalamic deep brain stimulation for tremor: an underestimated yet common side effect. J Neurol Neurosurg Psychiatry 2016;87(5):565-567. |
| 33. | Marek M, Paus S, Allert N, Mädler B, Klockgether T, Urbach H, Coenen VA. Ataxia and tremor due to lesions involving cerebellar projection pathways: a DTI tractographic study in six patients. J Neurol 2015;262(1):54-58. |
| 32. | Coenen VA, Allert N, Paus S, Kronenbürger M, Urbach H, Mädler B. Modulation of the Cerebello-thalamo-cortical Network in Thalamic Deep Brain Stimulation for Tremor: A Diffusion Tensor Imaging Study. Neurosurgery 2014;75(6):657-669. |
| 31. | Dressler D, Kupsch A, Seitzinger A, Paus S. The Dystonia Discomfort Scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia. Eur J Neurol 2014;21(3):459-462. |
| 30. | Jankowski J*, Paus S*, Scheef L, Bewersdorff M, Schild HH, Klockgether T, Boecker H. Abnormal movement preparation in task-specific focal hand dystonia. PLoS One 2013;8(10):e78234. * |
| 29. | Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A. Long-term efficacy and safety of incobotulinumtoxinA (Xeomin®) injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry 2013;84(9):1014-1019. |
| 28. | Marek M, Klockgether T, Urbach H, Zerr I, Kretzschmar H, Paus S. Isolated spasticity in sporadic Creutzfeldt-Jakob disease. J Neurol 2013;260(2):654-655. |
| 27. | Kaut O, Asmus F, Paus S. Spontaneous unwelcome orgasms due to pramipexole and ropinirole. Mov Disord. 2012;27(10):1327-1328. |
| 26. | Hefter H, Kupsch A, Müngersdorf M, Paus S, Stenner A, Jost W; on behalf of the Dysport Cervical Dystonia Study Group. A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. Brit Med J Open 2011;1(2):e000196. |
| 25. | Sajonz B, Mädler B, Herberhold S, Paus S, Coenen VA. A case of tremor reduction and almost complete ageusia under bilateral thalamic (VIM) deep brain stimulation in essential tremor-a therapeutic dilemma. Acta Neurochir (Wien) 2011;153(12):2361-2363. |
| 24. | Kaut O, Allert N, Coch C, Paus S, Grezeska A, Minnerop M, Wüllner U. Stochastic resonance therapy improves tremor and bradykinesia in PD. NeuroRehabilitation 2011;28(4):353-358. |
| 23. | Paus S, Gross M, Moll-Mueller M, Hentschel F, Spottke A, Wabbels B, Klockgether T, Abele M. Impaired sleep quality and restless legs syndrome in idiopathic focal dystonia: a controlled study. J Neurol 2011;258(10):1835-1840. |
| 22. | Paus S, Gadow F, Kaut O, Knapp M, Klein C, Klockgether T, Wüllner U. Tremor in Parkinson’s disease is not associated to the DRD3 Ser9Gly polymorphism. Parkinsonism Relat D 2010;16(6):381-383. |
| 21. | Paus S, Gadow F, Knapp M, Klein C, Klockgether T, Wüllner U. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Mov Disord 2009;24(7):1080-1084. |
| 20. | Rakovic A, Stiller B, Djarmati A, Flaquer A, Freudenberg J, Toliat MR, Linnebank M, Kostic V, Lohmann K, Paus S, Nürnberg P, Kubisch C, Klein C, Wüllner U, Ramirez A. Genetic association study of the P-type ATPase ATP13A2 in late-onset Parkinson's disease. Mov Disord 2009;24(3):429-433. |
| 19. | Paus S, Zsurka G, Baron M, Deschauer M, Bamberg C, Klockgether T, Kunz WS, Kornblum C. Apraxia of lid opening mimicking ptosis in compound heterozygosity for A467T and W748S POLG1 mutations. Mov Disord 2008;23(9):1286-1288. |
| 18. | Paus S, Grünewald A,Klein C, Knapp M, Zimprich A, Janetzky B, Möller C, Klockgether T,Wüllner U. The DRD2TaqIA polymorphism and demand of dopaminergic medication in Parkinson’s disease. Mov Disord 2008;23(4):599-602. |
| 17. | Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Effects of bright light therapy on motor symptoms, depression, and sleep in PD. Mov Disord 2007;22(10):1495-1498. |
| 16. | Paus S, Bigalke H, Klockgether T. Neutralizing antibodies against botulinum toxin A after a wasp sting. Arch Neurol 2006;63(12):1808-1809. |
| 15. | Paus S, Urbach H, Klockgether T, Hartmann A. Acute hebephrenia. Arch Neurol 2005;62(8):1312-1313. |
| 14. | Paus S, Rietschel M, Schulze TG, Ohlraun S, Diaconu CC, Van Den Bogaert A, Maier W, Propping P, Cichon S, Nöthen MM. Systematic screening for mutations in the human N-methyl-D-aspartate receptor 1 gene in schizophrenic patients from the German population. Psychiat Genet 2004;14(4):233-234. |
| 13. | Paus S, Seeger G, Brecht HM, Koster J, El-Faddagh M, Nöthen MM, Klockgether T, Wüllner U. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Mov Disord 2004;19(6):705-707. |
| 12. | Möller JC, Depboylu C, Kölsch H, Lohmuller F, Bandmann O, Gocke P, Du Y, Paus S, Wüllner U, Gasser T, Oertel WH, Klockgether T, Dodel RC. Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease. Neurosci Lett 2004;359(3):195-197. |
| 11. | Paus S, Brecht HM, Klockgether T, Wüllner U. Reply on: Homann CN, Homann B, Ott E, Park KB. Sleep attacks may not be a side effect of dopaminergic medication. Mov Disord 2003;18(12):1569-1570; author reply |
| 10. | Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003;18(6):659-667. |
| 9. | Tschampa HJ, Murtz P, Flacke S, Paus S, Schild HH, Urbach H. Thalamic involvement in sporadic Creutzfeldt-Jakob disease: a diffusion-weighted MR imaging study. Am J Neuroradiol 2003;24(5):908-915. |
| 8. | Paus S, Prömse A, Schmidt S, Klockgether T. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology 2003;61(7):1022. |
| 7. | Fischer D, Paus S, Schröder R. Spätmanifestation einer Glykogenose Typ II. Nervenarzt 2003;74:896-899. |
| 6. | Paus S, Klockgether T, Urbach H, Schlegel U. Meningioma of the optic nerve sheath: treatment with hydroxyurea. J Neurol Neurosurg Psychiatry 2003;74(9):1348-1350. |
| 5. | Becker AJ, Chen J, Paus S, Beck H, Elger CE, Wiestler OD, Blümcke I. Transcriptional profiling in human epilepsy: expression array and single cell real-time qRT-PCR analysis reveal distinct cellular gene regulation. Neuroreport 2002;13(10):1327-1333. |
| 4. | Urbach H, Paus S, Tschampa HJ, Keller E, Schild HH. Creutzfeldt-Jakob Krankheit: Stellenwert der MRT. Fortschr Röntg 2001;173(6):509-514. |
| 3. | Paus S, Pötzsch B, Risse JH, Klockgether T, Wüllner U. Chorea and antiphospholipid antibodies: treatment with methotrexate. Neurology 2001;56(1):137-138. |
| 2. | Rietschel M, Krauss H, Müller DJ, Schulze TG, Knapp M, Marwinski K, Maroldt AO, Paus S, Grünhage F, Propping P, Maier W, Held T, Nöthen MM. Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000;250(1):31-35. |
| 1. | Rao D, Jonsson EG, Paus S, Ganguli R, Nöthen M, Nimgaonkar VL. Schizophrenia and the serotonin transporter gene. Psychiat Genet 1998;8(4):207-212. |
Fabiane Schuch
